// App-Quantinova.ai

TPS6099 : A phase II study of pembrolizumab and docetaxel for aggressive RAI refractory thyroid carcinomas or salivary gland cancers: The iPRIME study.

Researchers

Presenter

  • Tanguy Y. Seiwert

Principal Investigators

  • Jonas A. De Souza

  • Everett E. Vokes

  • Nishant Agrawal

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • The University of Chicago Medical Center, Chicago, IL

  • Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved